An analysis of the long-term efficacy of bimekizumab versus secukinumab found greater proportions of response and maintenance for the IL17A/F inhibitor. In the phase 3b BE RADIANT trial, 88.0% of bimekizumab and 79.1% of secukinumab responders reaching a Psoriasis Area and Severity Index (PASI) ≤2 at week 16 upheld response to week 48.
Data obtained from psoriatic patients has revealed that not only the achievement of clear or almost clear skin is very important, but also the durability of the therapy effect [1,2]. With this in mind, a post-hoc analysis of the phase 3b, head-to-head BE RADIANT trial (NCT03536884) was performed, which evaluated participants achieving a PASI ≤2 or 0 on bimekizumab or secukinumab at week 16 in their ability to maintain the response continuously through week 48 .
After randomisation, 743 trial participants received either 320 mg of bimekizumab 4- or 8-weekly or 300 mg of secukinumab every week until week 4 and every 4 weeks thereafter. Overall, baseline characteristics were evenly distributed except for the severity of psoriasis, noted as a higher percentage of Investigator’s Global Assessment (IGA) scale 4 in the bimekizumab arm (35.1%) versus the secukinumab group (27.6%).
Study results at week 16 revealed an achievement of PASI 0 in 61.7% in the bimekizumab arm and 48.9% in the secukinumab arm, whereas PASI ≤2 was found in 85.3% and 76.5%, respectively. Comparing the maintenance rates, 63.7% of participants on bimekizumab and 54.3% of those on secukinumab were able to retain PASI 0. A continuance of PASI ≤2 response from week 16 to 48 was detected in 88% of the bimekizumab and 79.1% of the secukinumab group. Of note, 93% (bimekizumab) and 87.4% (secukinumab) of study participants who started with a PASI 0 at week 16 held up a PASI ≤2 through to week 48.
So, in conclusion, the higher percentages of bimekizumab-treated participants reaching PASI 0 or ≤2 at week 16 versus those in the secukinumab arm were perpetuated into higher rates of continuous maintenance of response with ongoing treatment up to 48 weeks.
- Rasmussen MK, et al. Acta Derm Venereol. 2019;99:158-63.
- Tada Y, et al. J Dermatol. 2021;48:1665-74.
- Warren RB, et al. Bimekizumab versus Secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: post-hoc results from BE RADIANT phase 3B trial. P072, SPIN 2022 Congress, 06–08 July, Paris, France.
Copyright ©2022 Medicom Medical Publishers
« Greater PASI reductions lead to less impairment in social and sexual life Next Article
All patients with GPP benefit from IL-36 inhibitor therapy »
Table of Contents: SPIN 2022
Letter from the Editor
SPIN 2022 Highlights Podcast
IMIDs in Adults and Children: New Developments
Therapies for atopic dermatitis: still moving forward
Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant
Men on biologics report fewer adverse events than women
Conceptual framework of adverse drug reactions may improve treatment of patients with IMIDs
Psoriasis: The Beat Goes On
Systemic treatment for psoriasis: what is on the horizon?
Topical therapy in psoriasis: an important partner in combination therapy
GPP flares: pronounced undertreatment is common
IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab
Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas
Psoriasis patients see great benefit in achieving complete skin clearance
The Future Is Bright for Vitiligo
Predilection sites for skin signs of vitiligo disease activity determined
Where Are We Now in Hidradenitis Suppurativa
IHS4 better suited as an outcome measure in HS trials?
New treatments for HS: IL-17 inhibitors next in practice?
New Treatment Options in Alopecia Areata
Alopecia areata: light at the end of the tunnel
Alopecia areata pathogenesis: known genetic background, unknown environmental triggers
Best of the Posters
Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib
Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab
Dose tapering in psoriasis is associated with a low relapse rate
IL-17 blocker: effective and safe in patients with comorbidities
Psoriasis: New treatments and current pipeline